A Prospective, Open, Multicenter Clinical Trial of Eltrombopag Combined With Diacerein in Eltrombopag-inefficient or Relapsed ITP

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 1, 2019

Primary Completion Date

June 1, 2020

Study Completion Date

November 1, 2020

Conditions
Thrombocytopenia
Interventions
DRUG

Eltrombopag and Diacerein

The initial dose of eltrombopag administration is 25 mg orally once daily, which could be transited to 50 mg/d in a 2-week cycle according to the need, and the maximum dose was not more than 75 mg/d. The dose of diacerein administration is 50 mg orally twice daily. The treatment was discontinued after 6 weeks without blood index reaction.

Trial Locations (1)

Unknown

Qilu hospital, Shandong University, Jinan

All Listed Sponsors
collaborator

The Affiliated Hospital of the Chinese Academy of Military Medical Sciences

OTHER

collaborator

Anhui Medical University

OTHER

collaborator

The First Affiliated Hospital of Dalian Medical University

OTHER

collaborator

Shenzhen Second People's Hospital

OTHER

collaborator

Zhejiang Provincial Hospital of TCM

OTHER

lead

Shandong University

OTHER

NCT03754634 - A Prospective, Open, Multicenter Clinical Trial of Eltrombopag Combined With Diacerein in Eltrombopag-inefficient or Relapsed ITP | Biotech Hunter | Biotech Hunter